(Bloomberg) Runaway demand for Novo Nordisk A/S’s diabetes and weight-loss drugs has propelled the Danish drugmaker into a class all its own atop Europe’s pharmaceutical sector — and the Stoxx Europe 600 Index — so achieving its 2023 targets should be a shoo-in when it reports next week.Most Read from BloombergPutin Sends US Signal on Ukraine Talks, Seeing War AdvantageUS Extends Lead Over China in Race for World’s Biggest EconomyTesla Sinks After Warning About ‘Notably Lower’ Growth RateJPMo
Critical rhetoric and policy uncertainty tend to weigh on health-care stocks in presidential election years. But we like many in the industry this year.